Work

EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

Year: 2022

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2022.07.951

Authors: L. Paz-Ares, M. Reck, S. Peters, H. Borghaei, R. Herbst, M. Siddiqui, V. Cuchelkar, K. Bhatt, D. Chakrabarti, L. Wang, S. Morris, S.V. Liu

Institutions: Hospital Universitario 12 De Octubre, German Center for Lung Research, LungenClinic Grosshansdorf, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Fox Chase Cancer Center, Yale Cancer Center, Yale University, Genentech, Jazz Pharmaceuticals (United States), F. Hoffmann-La Roche AG, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4296767504

Cites:

Cited by: 13

Related to: 10